$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

$nwbo Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-K Financial Statement

#000114420415016579 Filed on March 17, 2015

Income Statement

Concept	2015 Q1	2014	2013 Q4
Revenue	$194.0K	$1.454M	$0.00
YoY Change		79.73%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.320M	$16.95M	$3.550M
YoY Change	-10.03%	37.13%	-52.79%
% of Gross Profit
Research & Development	$19.63M	$85.64M	$11.12M
YoY Change	-1.81%	95.05%	32.7%
% of Gross Profit
Depreciation & Amortization	$3.000K	$12.00K	$0.00
YoY Change		20.0%
% of Gross Profit
Operating Expenses	$19.63M	$85.64M	$14.67M
YoY Change	-1.81%	95.05%	-7.74%
Operating Profit	-$22.83M	-$101.1M
YoY Change	-3.59%	82.33%
Interest Expense	$793.0K	$996.0K	$930.0K
YoY Change	550.0%	18.29%	-115.92%
% of Operating Profit
Other Income/Expense, Net	-$23.60M	-$18.91M	-$3.150M
YoY Change	5.56%	78.35%	-65.38%
Pretax Income	-$46.43M	-$135.6M	-$16.89M
YoY Change	0.85%	106.16%	-44.66%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$46.43M	-$135.6M	-$16.89M
YoY Change	0.85%	106.17%	-44.66%
Net Earnings / Revenue	-23934.54%	-9328.34%
Basic Earnings Per Share	-$0.67
Diluted Earnings Per Share	-$0.67	-$2.289M	-$426.0K
COMMON SHARES
Basic Shares Outstanding	70.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.170M	$13.39M	$18.50M
YoY Change	-74.08%	-27.62%	151.7%
Cash & Equivalents	$3.170M	$13.39M	$18.50M
Short-Term Investments
Other Short-Term Assets	$1.550M	$387.0K	$150.0K
YoY Change	933.33%	158.0%	36.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.715M	$14.64M	$18.65M
YoY Change	-61.91%	-21.49%	150.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.39M	$40.00M	$83.00K
YoY Change	51632.5%	49898.75%	-12.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$55.00K	$1.815M	$55.00K
YoY Change	-8.33%	2925.0%	175.0%
Total Long-Term Assets	$44.70M	$41.81M	$138.0K
YoY Change	34283.08%	32064.62%	23.21%
TOTAL ASSETS
Total Short-Term Assets	$4.715M	$14.64M	$18.65M
Total Long-Term Assets	$44.70M	$41.81M	$138.0K
Total Assets	$49.41M	$56.46M	$18.78M
YoY Change	294.99%	200.62%	148.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.744M	$0.00	$8.937M
YoY Change	47.19%	-100.0%	9.45%
Accrued Expenses	$940.0K	$0.00	$842.0K
YoY Change	23.68%	-100.0%	42.95%
Deferred Revenue
YoY Change
Short-Term Debt	$930.0K	$934.0K	$930.0K
YoY Change	0.0%	0.43%	0.0%
Long-Term Debt Due	$240.0K	$6.366M	$290.0K
YoY Change	0.0%	2095.17%	-72.64%
Total Short-Term Liabilities	$90.97M	$75.01M	$19.69M
YoY Change	108.79%	280.94%	83.26%
LONG-TERM LIABILITIES
Long-Term Debt	$29.00M	$16.38M	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$148.0K	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$29.14M	$16.38M	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$90.97M	$75.01M	$19.69M
Total Long-Term Liabilities	$29.14M	$16.38M	$0.00
Total Liabilities	$120.1M	$91.48M	$19.69M
YoY Change	175.68%	364.62%	55.94%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$496.5M		$375.3M
YoY Change			23.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$70.70M	-$35.03M	-$9.818M
YoY Change
Total Liabilities & Shareholders Equity	$49.41M	$56.46M	$18.78M
YoY Change	294.99%	200.62%	148.14%

Cashflow Statement

Concept	2015 Q1	2014	2013 Q4
OPERATING ACTIVITIES
Net Income	-$46.43M	-$135.6M	-$16.89M
YoY Change	0.85%	106.17%	-44.66%
Depreciation, Depletion And Amortization	$3.000K	$12.00K	$0.00
YoY Change		20.0%
Cash From Operating Activities	-$17.58M	-$54.58M	-$14.60M
YoY Change	66.51%	44.38%	77.18%
INVESTING ACTIVITIES
Capital Expenditures	$1.133M	-$33.73M	$50.00K
YoY Change		3372600.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$4.500M
YoY Change
Cash From Investing Activities	-$1.133M	-$36.35M	$4.550M
YoY Change		-3635300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$8.510M	$85.82M	25.69M
YoY Change	98.37%	75.31%	65.85%
NET CHANGE
Cash From Operating Activities	-$17.58M	-$54.58M	-14.60M
Cash From Investing Activities	-$1.133M	-$36.35M	4.550M
Cash From Financing Activities	$8.510M	$85.82M	25.69M
Net Change In Cash	-$10.21M	-$5.109M	15.64M
YoY Change	62.79%	-145.81%	115.72%
FREE CASH FLOW
Cash From Operating Activities	-$17.58M	-$54.58M	-$14.60M
Capital Expenditures	$1.133M	-$33.73M	$50.00K
Free Cash Flow	-$18.72M	-$20.85M	-$14.65M
YoY Change	77.24%	-44.84%	77.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55000	USD
CY2013Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	138000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55000	USD
CY2014Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	43799000	USD
CY2013Q4	us-gaap	Assets Assets	18784000	USD
CY2013Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0	USD
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	1985000	USD
CY2013Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2013Q4	us-gaap	Liabilities Liabilities	19689000	USD
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	8913000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	842000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	375213000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	384887000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-190000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	934000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8937000	USD
CY2013Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	288000	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	934000	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	8688000	USD
CY2014Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	44742000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19689000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-9818000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	46000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18784000	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of equity instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply, and the fair value of environmental remediation liabilities. </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	17500000	USD
CY2014Q3	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.05	pure
CY2014Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.30
CY2014Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	16200000	USD
CY2014Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2000000	USD
CY2014Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	200000	USD
CY2013	nwbo	Cash Payments CashPayments	12400000	USD
CY2014	nwbo	Cash Payments CashPayments	18700000	USD
CY2013	nwbo	Cash Payments For Services CashPaymentsForServices	3600000	USD
CY2014	nwbo	Cash Payments For Services CashPaymentsForServices	5700000	USD
CY2013	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	43900000	USD
CY2014	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	85600000	USD
CY2014	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual High Estimate SiteContingencyLossExposureInExcessOfAccrualHighEstimate	4500000	USD
CY2014	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Low Estimate SiteContingencyLossExposureInExcessOfAccrualLowEstimate	32000000	USD
CY2014	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Best Estimate SiteContingencyLossExposureInExcessOfAccrualBestEstimate	6200000	USD
CY2013Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	3619000	USD
CY2014Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	5729000	USD
CY2013Q4	nwbo	Accrued Expenses Related Party AccruedExpensesRelatedParty	5000	USD
CY2014Q4	nwbo	Accrued Expenses Related Party AccruedExpensesRelatedParty	8000	USD
CY2013Q4	nwbo	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	75000	USD
CY2014Q4	nwbo	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	50000	USD
CY2013Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	1444788	shares
CY2014Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2013Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1444788	shares
CY2014Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45666315	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68957469	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45666315	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68957469	shares
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8700000	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5101366	shares
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2014Q3	nwbo	Warrants Issued During Period WarrantsIssuedDuringPeriod	2325467	shares
CY2014Q3	nwbo	Warrants Expiration Period WarrantsExpirationPeriod	P5Y
CY2014Q3	nwbo	Warrants Initial Exercise Price WarrantsInitialExercisePrice	4.00
CY2014	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	3.80
CY2014Q3	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	3.08
CY2014	nwbo	Lock Up Agreement Description LockUpAgreementDescription	The Company also entered into a Lock-Up Agreement with Cognate BioServices on January 17, 2014, under which Cognate BioServices agreed to have all of the shares that are issued as part of the Cognate BioServices Agreements (“Lock-Up Shares”) locked up for up to 36 months, in return for 15% warrant coverage for each 6-month period of lock-up, on the same terms as the warrants in the Cognate BioServices Agreements. During the lock-ups, the Lock-Up Shares may not be sold or traded on the market. These lock-up terms are subject to the same most favored nation treatment as provided in the Cognate BioServices Agreements, as described in Note 1.
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	231000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	40159000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	148000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	160000	USD
CY2014	us-gaap	Depreciation Depreciation	10000	USD
CY2013	us-gaap	Revenue From Grants RevenueFromGrants	809000	USD
CY2014	us-gaap	Revenue From Grants RevenueFromGrants	1454000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	809000	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	1454000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43906000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	85637000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12365000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16949000	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12000	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-55474000	USD
CY2013	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	10599000	USD
CY2014	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	18905000	USD
CY2013	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1157000	USD
CY2014Q3	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	1	shares
CY2013Q4	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	441	shares
CY2014Q4	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	43	shares
CY2013Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12177	shares
CY2014	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-15062000	USD
CY2013	us-gaap	Interest Expense InterestExpense	842000	USD
CY2014	us-gaap	Interest Expense InterestExpense	996000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-65789000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-135634000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.00
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.29
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32865000	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59248000	shares
CY2013Q4	nwbo	Convertible Notes Payable Current Related Parties ConvertibleNotesPayableCurrentRelatedParties	75000	USD
CY2014Q4	nwbo	Convertible Notes Payable Current Related Parties ConvertibleNotesPayableCurrentRelatedParties	50000	USD
CY2013Q4	us-gaap	Notes Payable NotesPayable	1222000	USD
CY2014Q4	us-gaap	Notes Payable NotesPayable	1172000	USD
CY2014	nwbo	Percentage Of Initial Purchase Price PercentageOfInitialPurchasePrice	0.3	pure
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19232000	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33415000	shares
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	13500000	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	16800000	USD
CY2014Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	8900000	USD
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	8900000	USD
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	1900000	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	1900000	USD
CY2014Q1	nwbo	Potential Redeemable Shares Eligible PotentialRedeemableSharesEligible	1400000	shares
CY2013Q4	nwbo	Potential Redeemable Shares Eligible PotentialRedeemableSharesEligible	383315	shares
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12086	shares
CY2014Q1	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Cognate Accounts Payable ClassOfWarrantOrRightIssuedInConnectionWithConversionOfCognateAccountsPayable	741	shares
CY2014Q2	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Cognate Accounts Payable ClassOfWarrantOrRightIssuedInConnectionWithConversionOfCognateAccountsPayable	364	shares
CY2013Q3	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Cognate Accounts Payable ClassOfWarrantOrRightIssuedInConnectionWithConversionOfCognateAccountsPayable	2116	shares
CY2014Q3	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Cognate Accounts Payable ClassOfWarrantOrRightIssuedInConnectionWithConversionOfCognateAccountsPayable	1121	shares
CY2013Q4	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Cognate Accounts Payable ClassOfWarrantOrRightIssuedInConnectionWithConversionOfCognateAccountsPayable	240	shares
CY2013Q1	nwbo	Number Of Warrants Warrants Issued In Exchange For Services NumberOfWarrantsWarrantsIssuedInExchangeForServices	109	shares
CY2014Q1	nwbo	Number Of Warrants Warrants Issued In Exchange For Services NumberOfWarrantsWarrantsIssuedInExchangeForServices	2434	shares
CY2014Q3	nwbo	Number Of Warrants Warrants Issued In Exchange For Services NumberOfWarrantsWarrantsIssuedInExchangeForServices	17	shares
CY2013Q4	nwbo	Number Of Warrants Warrants Issued In Exchange For Services NumberOfWarrantsWarrantsIssuedInExchangeForServices	74	shares
CY2014Q1	nwbo	Class Of Warrant Or Right Issued To Connection With Common Stock Issued ClassOfWarrantOrRightIssuedToConnectionWithCommonStockIssued	150	shares
CY2014Q2	nwbo	Class Of Warrant Or Right Issued To Connection With Common Stock Issued ClassOfWarrantOrRightIssuedToConnectionWithCommonStockIssued	281	shares
CY2014Q3	nwbo	Number Of Warrants Warrants Issued To Cognate For Services NumberOfWarrantsWarrantsIssuedToCognateForServices	2326	shares
CY2014Q1	nwbo	Number Of Warrants Warrants Exercised On Cashless Basis NumberOfWarrantsWarrantsExercisedOnCashlessBasis	73	shares
CY2013Q2	nwbo	Number Of Warrants Warrants Exercised On Cashless Basis NumberOfWarrantsWarrantsExercisedOnCashlessBasis	168	shares
CY2014Q1	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	722	shares
CY2014Q2	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	90	shares
CY2014Q3	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	497	shares
CY2013Q4	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	179	shares
CY2013Q2	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOffering	1026	shares
CY2014Q2	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOffering	2273	shares
CY2013Q3	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOffering	2239	shares
CY2014Q3	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOffering	2735	shares
CY2013Q4	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOffering	2815	shares
CY2013Q2	nwbo	Class Of Warrant Or Right Issued To Placement Agent In Connection With Registered Direct Offering ClassOfWarrantOrRightIssuedToPlacementAgentInConnectionWithRegisteredDirectOffering	128	shares
CY2014Q2	nwbo	Class Of Warrant Or Right Issued To Placement Agent In Connection With Registered Direct Offering ClassOfWarrantOrRightIssuedToPlacementAgentInConnectionWithRegisteredDirectOffering	113	shares
CY2013Q1	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	18	shares
CY2014Q1	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	6	shares
CY2013Q2	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	18	shares
CY2013Q3	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	19	shares
CY2014Q1	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	5.12
CY2013Q2	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	6.78
CY2014Q2	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	5.32
CY2013Q3	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	6.07
CY2014Q3	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	4.90
CY2013Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	5.23
CY2014Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	4.72
CY2014Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	238496	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	22640	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13145	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	25581	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	17554	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	28962	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20116	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	29385	shares
CY2012Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	6.18
CY2014Q1	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Debt Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithConversionOfDebtWeightedAverageExercisePrice	4.00
CY2014Q2	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Debt Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithConversionOfDebtWeightedAverageExercisePrice	4.00
CY2013Q3	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Debt Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithConversionOfDebtWeightedAverageExercisePrice	4.00
CY2014Q3	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Debt Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithConversionOfDebtWeightedAverageExercisePrice	4.00
CY2013Q4	nwbo	Class Of Warrant Or Right Issued In Connection With Conversion Of Debt Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithConversionOfDebtWeightedAverageExercisePrice	4.00
CY2013Q1	nwbo	Class Of Warrant Or Right Issued In Exchange Of Services Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInExchangeOfServicesWeightedAverageExercisePrice	6.40
CY2014Q1	nwbo	Class Of Warrant Or Right Issued In Exchange Of Services Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInExchangeOfServicesWeightedAverageExercisePrice	4.00
CY2014Q3	nwbo	Class Of Warrant Or Right Issued In Exchange Of Services Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInExchangeOfServicesWeightedAverageExercisePrice	6.33
CY2013Q4	nwbo	Class Of Warrant Or Right Issued In Exchange Of Services Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInExchangeOfServicesWeightedAverageExercisePrice	5.00
CY2014Q1	nwbo	Class Of Warrant Or Right Issued To Connection With Common Stock Weighted Average Exercise Price ClassOfWarrantOrRightIssuedToConnectionWithCommonStockWeightedAverageExercisePrice	5.00
CY2014Q2	nwbo	Class Of Warrant Or Right Issued To Connection With Common Stock Weighted Average Exercise Price ClassOfWarrantOrRightIssuedToConnectionWithCommonStockWeightedAverageExercisePrice	4.00
CY2014Q3	nwbo	Class Of Warrant Or Right Issued To Cognate For Services Weighted Average Exercise Price ClassOfWarrantOrRightIssuedToCognateForServicesWeightedAverageExercisePrice	4.00
CY2014Q1	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	3.66
CY2014Q2	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	4.25
CY2014Q3	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	3.48
CY2013Q4	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	3.35
CY2014Q1	nwbo	Weighted Average Exercise Pricewarrants Exercised On Cashless Basis WeightedAverageExercisePricewarrantsExercisedOnCashlessBasis	0
CY2013Q2	nwbo	Weighted Average Exercise Pricewarrants Exercised On Cashless Basis WeightedAverageExercisePricewarrantsExercisedOnCashlessBasis	5.60
CY2013Q2	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOfferingWeightedAverageExercisePrice	4.29
CY2014Q2	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOfferingWeightedAverageExercisePrice	7.50
CY2013Q3	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOfferingWeightedAverageExercisePrice	4.00
CY2014Q3	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOfferingWeightedAverageExercisePrice	5.15
CY2013Q4	nwbo	Class Of Warrant Or Right Issued In Connection With Registered Direct Offering Weighted Average Exercise Price ClassOfWarrantOrRightIssuedInConnectionWithRegisteredDirectOfferingWeightedAverageExercisePrice	6.00
CY2013Q2	nwbo	Class Of Warrant Or Right Issued To Placement Agent In Connection With Registered Direct Offering In Exchange Of Services Weighted Average Exercise Price ClassOfWarrantOrRightIssuedToPlacementAgentInConnectionWithRegisteredDirectOfferingInExchangeOfServicesWeightedAverageExercisePrice	4.29
CY2014Q2	nwbo	Class Of Warrant Or Right Issued To Placement Agent In Connection With Registered Direct Offering In Exchange Of Services Weighted Average Exercise Price ClassOfWarrantOrRightIssuedToPlacementAgentInConnectionWithRegisteredDirectOfferingInExchangeOfServicesWeightedAverageExercisePrice	8.25
CY2013Q1	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	15.45
CY2014Q1	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	9.54
CY2013Q2	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	12.00
CY2013Q3	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	12.00
CY2014Q3	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	7.63
CY2013Q4	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	11.94
CY2014Q4	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	8.14
CY2013Q1	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	6.82
CY2013Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	178504	shares
CY2014Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	24924	shares
CY2013Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	14326	shares
CY2014Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	14519	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	141330	shares
CY2013Q4	nwbo	Stock Issued During Period For Convertible Accounts StockIssuedDuringPeriodForConvertibleAccounts	1818000	shares
CY2013	nwbo	Inducement Expenses InducementExpenses	10465000	USD
CY2014	nwbo	Inducement Expenses InducementExpenses	18905000	USD
CY2013	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	35000	USD
CY2014	nwbo	Fair Value Of Common Stock For Convertible Accounts FairValueOfCommonStockForConvertibleAccounts	8700000	USD
CY2013Q4	nwbo	Fair Value Of Common Stock For Convertible Accounts FairValueOfCommonStockForConvertibleAccounts	6700000	USD
CY2014Q1	nwbo	Inducement Expenses InducementExpenses	5300000	USD
CY2013Q4	nwbo	Inducement Expenses InducementExpenses	1500000	USD
CY2014Q1	nwbo	Redeemable Shares Number RedeemableSharesNumber	1444788	shares
CY2013Q4	nwbo	Redeemable Shares Number RedeemableSharesNumber	41667	shares
CY2014Q1	nwbo	Stock Issued During Period Shares Exercise Of Warrant StockIssuedDuringPeriodSharesExerciseOfWarrant	721827	shares
CY2014Q1	nwbo	Stock Issued During Period Value Exercise Of Warrant StockIssuedDuringPeriodValueExerciseOfWarrant	2700000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1600000	USD
CY2014Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	155607	USD
CY2014Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	94999	USD
CY2014Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2272727	shares
CY2014Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2272727	shares
CY2014Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	15000000	USD
CY2014Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	4500000	USD
CY2014Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	11500000	USD
CY2014Q3	nwbo	Fair Value Of Warrants At Issuance Date FairValueOfWarrantsAtIssuanceDate	3800000	USD
CY2014Q3	nwbo	Reclassification Of Equity Instruments Shares ReclassificationOfEquityInstrumentsShares	3013	shares
CY2014Q3	nwbo	Reclassification Of Equity Instruments Shares ReclassificationOfEquityInstrumentsShares	49107	shares
CY2014Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.60
CY2014Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.05
CY2014Q1	nwbo	Proceeds From Shares Payable ProceedsFromSharesPayable	1400000	USD
CY2014Q2	nwbo	Proceeds From Shares Payable ProceedsFromSharesPayable	1400000	USD
CY2014Q3	nwbo	Proceeds From Shares Payable ProceedsFromSharesPayable	15000	USD
CY2014Q3	nwbo	Proceeds From Shares Payable ProceedsFromSharesPayable	275000	USD
CY2014Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	92100	shares
CY2014Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	497133	shares
CY2014Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1700000	USD
CY2013Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5600000	USD
CY2014Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7900000	USD
CY2014Q1	nwbo	Value Of Notes Converted To Common Stock ValueOfNotesConvertedToCommonStock	200000	USD
CY2014Q1	nwbo	Number Of Common Shares From Notes Conversion NumberOfCommonSharesFromNotesConversion	70000	shares
CY2014Q1	nwbo	Reclassification Of Redeemable Shares To Equity Value ReclassificationOfRedeemableSharesToEquityValue	8900000	USD
CY2014Q2	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	125550	USD
CY2014Q2	nwbo	Proceed From Exercise Of Warrants ProceedFromExerciseOfWarrants	394925	USD
	nwbo	Warrants Issued During Period WarrantsIssuedDuringPeriod	14261000	shares
	nwbo	Warrants Issued Weighted Average Exercise Price Per Warrant WarrantsIssuedWeightedAverageExercisePricePerWarrant	4.00
	nwbo	Warrants Issuedweighted Average Remaining Contractual Term WarrantsIssuedweightedAverageRemainingContractualTerm	P3Y9M18D
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-16073000	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	53026000	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	15000000	USD
CY2014	nwbo	Stock Issued During Period Value Private Placement Net Of Offering Costs StockIssuedDuringPeriodValuePrivatePlacementNetOfOfferingCosts	2059000	USD
CY2014	nwbo	Adjustment To Additional Paid In Capital Inducement Expenses Associated With Conversion Convertible Debt AdjustmentToAdditionalPaidInCapitalInducementExpensesAssociatedWithConversionConvertibleDebt	8654000	USD
CY2014	nwbo	Stock Issued During Period Value Conversion Of Note Payable And Accrued Interest StockIssuedDuringPeriodValueConversionOfNotePayableAndAccruedInterest	217000	USD
CY2014	nwbo	Cashless Exercises Of Warrants Value CashlessExercisesOfWarrantsValue	0	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3955000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1105000	USD
CY2013	nwbo	Stock Issued During Period Value Issued For Services Non Employees StockIssuedDuringPeriodValueIssuedForServicesNonEmployees	2341000	USD
CY2014	nwbo	Stock Issued During Period Value Issued For Services Non Employees StockIssuedDuringPeriodValueIssuedForServicesNonEmployees	1817000	USD
CY2014	nwbo	Stock And Warrants Value Issued StockAndWarrantsValueIssued	2250000	USD
CY2014	nwbo	Stock Issued During Period Value Proceeds From Warrants Exercises StockIssuedDuringPeriodValueProceedsFromWarrantsExercises	4817000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1525000	USD
CY2014	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	8665000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	212000	USD
CY2013	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	11000	USD
CY2014	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	11000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	531000	USD
CY2013	nwbo	Accrued Interest Converted To Preferred Stock AccruedInterestConvertedToPreferredStock	0	USD
CY2014	nwbo	Accrued Interest Converted To Preferred Stock AccruedInterestConvertedToPreferredStock	77000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1350000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2013	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	0	USD
CY2014	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	21329000	USD
CY2013	nwbo	Stock And Warrants Issued For Services And Other Expenses StockAndWarrantsIssuedForServicesAndOtherExpenses	2341000	USD
CY2014	nwbo	Stock And Warrants Issued For Services And Other Expenses StockAndWarrantsIssuedForServicesAndOtherExpenses	1819000	USD
CY2014	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	240000	USD
CY2013	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	766000	USD
CY2014	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	4989000	USD
CY2013	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	13754000	USD
CY2014	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	19343000	USD
CY2013	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	37000	USD
CY2014	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37800000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54576000	USD
CY2013	nwbo	Payments For Proceeds From Property And Equipment Net PaymentsForProceedsFromPropertyAndEquipmentNet	-1000	USD
CY2014	nwbo	Payments For Proceeds From Property And Equipment Net PaymentsForProceedsFromPropertyAndEquipmentNet	33727000	USD
CY2013	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2014	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2625000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36352000	USD
CY2013	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	1630000	USD
CY2014	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	USD
CY2013	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1605000	USD
CY2014	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	25000	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	17500000	USD
CY2013	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	499000	USD
CY2014	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	595000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4817000	USD
CY2013	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2250000	USD
CY2013	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	53026000	USD
CY2014	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	40235000	USD
CY2013	nwbo	Proceeds From Issuance Of Common Stock Over Allotment Rights ProceedsFromIssuanceOfCommonStockOverAllotmentRights	0	USD
CY2014	nwbo	Proceeds From Issuance Of Common Stock Over Allotment Rights ProceedsFromIssuanceOfCommonStockOverAllotmentRights	13895000	USD
CY2013	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3955000	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48952000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	85819000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11153000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5109000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7346000	USD
CY2013	nwbo	Reclass Of Redeemable Security To Equity ReclassOfRedeemableSecurityToEquity	217000	USD
CY2014	nwbo	Reclass Of Redeemable Security To Equity ReclassOfRedeemableSecurityToEquity	8913000	USD
CY2013	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1864000	USD
CY2014	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2013	us-gaap	Environmental Expense And Liabilities EnvironmentalExpenseAndLiabilities	0	USD
CY2014	us-gaap	Environmental Expense And Liabilities EnvironmentalExpenseAndLiabilities	6200000	USD
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Entity Registrant Name EntityRegistrantName	NORTHWEST BIOTHERAPEUTICS INC
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001072379
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	235623851	USD
CY2014	dei	Trading Symbol TradingSymbol	NWBO
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70310724	shares
CY2013Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2014Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	6990000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	98000	USD
CY2013	nwbo	Accretion Of Redeemable Securities AccretionOfRedeemableSecurities	31000	USD
CY2014	nwbo	Accretion Of Redeemable Securities AccretionOfRedeemableSecurities	0	USD
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	23000	USD
CY2013Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	900000	USD
CY2013Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4477612	USD
CY2013Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	316000	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5630208	shares
CY2013Q1	nwbo	Stock Issued During Period For Convertible Notes StockIssuedDuringPeriodForConvertibleNotes	359000	shares
CY2013Q4	nwbo	Stock Issued During Period For Convertible Notes StockIssuedDuringPeriodForConvertibleNotes	150000	shares
CY2013Q1	nwbo	Fair Value Price Per Share FairValuePricePerShare	2.60
CY2013Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	235593	shares
CY2013Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	900000	USD
CY2013Q2	nwbo	Fair Value Of Common Stock Issued In Exchange For Redemption Period Extension FairValueOfCommonStockIssuedInExchangeForRedemptionPeriodExtension	600000	USD
CY2013Q3	nwbo	Fair Value Of Common Stock Issued In Exchange For Redemption Period Extension FairValueOfCommonStockIssuedInExchangeForRedemptionPeriodExtension	100000	USD
CY2013Q4	nwbo	Fair Value Of Common Stock Issued In Exchange For Redemption Period Extension FairValueOfCommonStockIssuedInExchangeForRedemptionPeriodExtension	2700000	USD
CY2013Q4	nwbo	Fair Value Of Common Stock Issued In Exchange For Redemption Period Extension FairValueOfCommonStockIssuedInExchangeForRedemptionPeriodExtension	27000000	USD
CY2013Q2	nwbo	Stock Issued During Period New Issues Price Per Share StockIssuedDuringPeriodNewIssuesPricePerShare	2.90
CY2013Q4	nwbo	Stock Issued During Period New Issues Price Per Share StockIssuedDuringPeriodNewIssuesPricePerShare	4.80
CY2013Q2	nwbo	Common Stock Closing Market Price CommonStockClosingMarketPrice	3.90
CY2013Q3	nwbo	Common Stock Closing Market Price CommonStockClosingMarketPrice	3.46
CY2013Q4	nwbo	Common Stock Closing Market Price CommonStockClosingMarketPrice	4.80
CY2013Q4	nwbo	Common Stock Purchase Warrants CommonStockPurchaseWarrants	2815104	shares
CY2013Q2	nwbo	Warrants Offering Cost WarrantsOfferingCost	800000	USD
CY2013Q4	nwbo	Warrants Offering Cost WarrantsOfferingCost	2000000	USD
CY2014Q1	nwbo	Number Of Common Stock Warrants Exercisable NumberOfCommonStockWarrantsExercisable	41310	shares
CY2013Q2	nwbo	Number Of Common Stock Warrants Exercisable NumberOfCommonStockWarrantsExercisable	168354	shares
CY2013Q4	nwbo	Number Of Common Stock Warrants Exercisable NumberOfCommonStockWarrantsExercisable	179094	shares
CY2012	nwbo	Redemption Provisions Term RedemptionProvisionsTerm	P9Y
CY2013Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.35
CY2014Q3	nwbo	Number Of Warrants Adjustment Related To Prior Issued Warrants NumberOfWarrantsAdjustmentRelatedToPriorIssuedWarrants	415	shares
CY2013Q4	nwbo	Stock Issued During Period Shares Issued In Exchange For Redemption Period Extension StockIssuedDuringPeriodSharesIssuedInExchangeForRedemptionPeriodExtension	733104	shares
CY2013	nwbo	Warrant Liability Recorded In Connection With Issuance Of Common Stock WarrantLiabilityRecordedInConnectionWithIssuanceOfCommonStock	-5602000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10000000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	15000000	USD
CY2013Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	27000000	USD
CY2013Q2	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	4.29
CY2013Q4	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	6.00
CY2013Q3	nwbo	Fair Value Of Common Stock Issued In Exchange For Services FairValueOfCommonStockIssuedInExchangeForServices	100000	USD
CY2013Q4	nwbo	Fair Value Of Common Stock Issued In Exchange For Services FairValueOfCommonStockIssuedInExchangeForServices	700000	USD
CY2013Q3	nwbo	Stock Issued During Period Shares Issued In Exchange For Redemption Period Extension StockIssuedDuringPeriodSharesIssuedInExchangeForRedemptionPeriodExtension	30000	shares
CY2014	nwbo	Adjustments To Additional Paid In Capital Redeemable Securities Settlement Value AdjustmentsToAdditionalPaidInCapitalRedeemableSecuritiesSettlementValue	398000	USD
CY2013	nwbo	Noncash Or Partial Noncash Transaction Deferred Offering Cost Related To Mortgage Loan NoncashOrPartialNoncashTransactionDeferredOfferingCostRelatedToMortgageLoan	0	USD
CY2014	nwbo	Noncash Or Partial Noncash Transaction Deferred Offering Cost Related To Mortgage Loan NoncashOrPartialNoncashTransactionDeferredOfferingCostRelatedToMortgageLoan	98000	USD
CY2013	us-gaap	Proceeds From Sale Of Mortgage Loans Held For Sale ProceedsFromSaleOfMortgageLoansHeldForSale	0	USD
CY2014	us-gaap	Proceeds From Sale Of Mortgage Loans Held For Sale ProceedsFromSaleOfMortgageLoansHeldForSale	6990000	USD
CY2013	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2059000	USD
CY2014Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7900000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1350000	USD
CY2013	nwbo	Warrants To Warrants Liability WarrantsToWarrantsLiability	217000	USD
CY2013Q4	nwbo	Fair Value Of Common Stock For Convertible Notes FairValueOfCommonStockForConvertibleNotes	500000	USD
CY2013Q3	nwbo	Stock Issued During Period For Convertible Notes In2012 StockIssuedDuringPeriodForConvertibleNotesIn2012	164155	shares
CY2013Q4	nwbo	Restricted Stock Fair Value Per Share RestrictedStockFairValuePerShare	3.68
CY2013Q4	nwbo	Redeemed Shares Value RedeemedSharesValue	200000	USD
CY2013Q4	nwbo	Warrants Exercise Price WarrantsExercisePrice	6.00
CY2013Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	25000000	USD
CY2014Q4	nwbo	Deferred Tax Assets Tax Credit Carry Forward Unused Research And Development DeferredTaxAssetsTaxCreditCarryForwardUnusedResearchAndDevelopment	9900000	USD
CY2014Q4	nwbo	Deferred Tax Asset Operating Loss Carry Forward DeferredTaxAssetOperatingLossCarryForward	339000000	USD
CY2012Q3	nwbo	Office Space Taken Under Lease Agreement OfficeSpaceTakenUnderLeaseAgreement	7,097 square feet
CY2013Q4	nwbo	Office Space Taken Under Lease Agreement OfficeSpaceTakenUnderLeaseAgreement	4,251 square feet
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2012	nwbo	Debt Converted To Redeemable Common Stock Value DebtConvertedToRedeemableCommonStockValue	4600000	USD
CY2012	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	5300000	USD
CY2012	nwbo	Redeemable Securities Accretion Expense RedeemableSecuritiesAccretionExpense	2000000	USD
CY2013Q3	nwbo	Extension Agreement Redeemable Shares Number ExtensionAgreementRedeemableSharesNumber	398920	shares
CY2013Q4	nwbo	Extension Agreement Redeemable Shares Number ExtensionAgreementRedeemableSharesNumber	520833	shares
CY2013Q4	nwbo	Warrants Issued In Exchange For Redemption Period Extension WarrantsIssuedInExchangeForRedemptionPeriodExtension	68750	shares
CY2013Q4	nwbo	Extension Agreement Redemption Date ExtensionAgreementRedemptionDate	2014-02-25
CY2013Q3	nwbo	Inducement Expenses InducementExpenses	200000	USD
CY2013Q4	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	200000	USD
CY2013	nwbo	Stock Issued During Period Value Conversion Of Notes Payable StockIssuedDuringPeriodValueConversionOfNotesPayable	2869000	USD
CY2013	nwbo	Stock And Warrants Value Issued For Redeemable Security Extension StockAndWarrantsValueIssuedForRedeemableSecurityExtension	2804000	USD
CY2013	nwbo	Reclassification Common Par To Additional Paid In Capital ReclassificationCommonParToAdditionalPaidInCapital	0	USD
CY2013Q4	nwbo	Redeemable Shares RedeemableShares	41667	shares
CY2013	nwbo	Exercises Of Warrants Value ExercisesOfWarrantsValue	595000	USD
CY2014	nwbo	Adjustments To Additional Paid In Capital Stock Issued Deferred Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedDeferredIssuanceCosts	197000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.007	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.004	pure
CY2014Q4	nwbo	Number Of Warrants Adjustment Related To Prior Issued Warrants NumberOfWarrantsAdjustmentRelatedToPriorIssuedWarrants	4	shares
CY2014Q4	nwbo	Class Of Warrant Or Right Canceled ClassOfWarrantOrRightCanceled	-2273	shares
CY2014Q4	nwbo	Class Of Warrant Or Right Canceled Weighted Average Exercise Price ClassOfWarrantOrRightCanceledWeightedAverageExercisePrice	7.50
CY2014Q3	nwbo	Weighted Average Exercise Price Adjustment Related To Prior Issued Warrants WeightedAverageExercisePriceAdjustmentRelatedToPriorIssuedWarrants	6.44
CY2014Q4	nwbo	Weighted Average Exercise Price Adjustment Related To Prior Issued Warrants WeightedAverageExercisePriceAdjustmentRelatedToPriorIssuedWarrants	5.60
CY2013	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2014	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	449000	USD
CY2013Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	0	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	865000	USD
CY2013Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	0	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	1760000	USD
CY2013Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	0	USD
CY2014Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6200000	USD
CY2013	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	240000	USD
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2014	nwbo	Lock Up Period Of Conversion Feature LockUpPeriodOfConversionFeature	P36M
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	99058000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	133684000	USD
CY2013Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4048000	USD
CY2014Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	9911000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	9094000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26510000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	112200000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	170105000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	112200000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	170105000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.054	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.054	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.413	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.434	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0	pure
CY2014Q4	nwbo	Amount Of Reduction Under Short Swing AmountOfReductionUnderShortSwing	448000	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	21189000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	49912000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2013	nwbo	Reclassification Of Redeemable Shares Value To Stockholders Equity ReclassificationOfRedeemableSharesValueToStockholdersEquity	1864000	USD
CY2014	nwbo	Reclassification Of Redeemable Shares Value To Stockholders Equity ReclassificationOfRedeemableSharesValueToStockholdersEquity	8913000	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3393000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	7993000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	24582000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	57905000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q4	us-gaap	Accrued Environmental Loss Contingencies Noncurrent AccruedEnvironmentalLossContingenciesNoncurrent	6200000	USD
CY2014	nwbo	Stock Issued During Period Value Issued For Cash One StockIssuedDuringPeriodValueIssuedForCashOne	40235000	USD
CY2014	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P15Y
CY2014	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	500000	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	20000	USD
CY2013Q3	nwbo	Class Of Warrant Or Right Issued For Extension Of Redeemable Securities ClassOfWarrantOrRightIssuedForExtensionOfRedeemableSecurities	73	shares
CY2013Q4	nwbo	Class Of Warrant Or Right Issued For Extension Of Redeemable Securities ClassOfWarrantOrRightIssuedForExtensionOfRedeemableSecurities	53	shares
CY2013Q3	nwbo	Class Of Warrant Or Right Issued For Extension Of Redeemable Securities Weighted Average Exercise Price ClassOfWarrantOrRightIssuedForExtensionOfRedeemableSecuritiesWeightedAverageExercisePrice	4.00
CY2013Q4	nwbo	Class Of Warrant Or Right Issued For Extension Of Redeemable Securities Weighted Average Exercise Price ClassOfWarrantOrRightIssuedForExtensionOfRedeemableSecuritiesWeightedAverageExercisePrice	6.40
CY2014Q3	us-gaap	Escrow Deposit EscrowDeposit	2600000	USD
CY2014	nwbo	Stock Issued During Period Shares Conversion Of Accounts Payable To Common Stock And Warrants StockIssuedDuringPeriodSharesConversionOfAccountsPayableToCommonStockAndWarrants	16800000	shares
CY2014Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	13400000	USD
CY2014Q4	nwbo	Current Assets Less Payables CurrentAssetsLessPayables	54200000	USD
CY2014Q4	nwbo	Convertible Notes Payable Related Parties ConvertibleNotesPayableRelatedParties	5700000	USD
CY2014Q4	nwbo	Working Capital Deficit WorkingCapitalDeficit	135600000	USD
CY2014	nwbo	Share Based Compensation Aggregate Non Cash Charges For Non Cash Interest Associated With Accretion Of Our Convertible Notes Discount Net ShareBasedCompensationAggregateNonCashChargesForNonCashInterestAssociatedWithAccretionOfOurConvertibleNotesDiscountNet	57000000	USD
CY2013	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2014	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	622000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.026	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.044	pure
CY2014Q4	nwbo	Noncash Derivative Liability NoncashDerivativeLiability	44700000	USD
CY2014Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	54200000	USD
CY2013	nwbo	Stock Issued During Period Value Conversion Of Accounts Payable To Common Stock StockIssuedDuringPeriodValueConversionOfAccountsPayableToCommonStock	16969000	USD
CY2014	nwbo	Computation Of Corporate Tax Rate ComputationOfCorporateTaxRate	0.4	pure
CY2013	nwbo	Computation Of Corporate Tax Rate ComputationOfCorporateTaxRate	0.4	pure
CY2014	nwbo	Stock Issued During Period Value Conversion Of Accounts Payable To Common Stock StockIssuedDuringPeriodValueConversionOfAccountsPayableToCommonStock	16781000	USD
CY2014	nwbo	Proceed From Deferred Offering Cost Releated To Convertible Note ProceedFromDeferredOfferingCostReleatedToConvertibleNote	-1280000	USD
CY2013	nwbo	Proceed From Deferred Offering Cost Releated To Convertible Note ProceedFromDeferredOfferingCostReleatedToConvertibleNote	0	USD
CY2014	nwbo	Common Stock Warrants Outstanding CommonStockWarrantsOutstanding	12555198	shares

Files In Submission

Name	View Source	Status
0001144204-15-016579-index-headers.html	Edgar Link	pending
0001144204-15-016579-index.html	Edgar Link	pending
0001144204-15-016579.txt	Edgar Link	pending
0001144204-15-016579-xbrl.zip	Edgar Link	pending
diagram_1.jpg	Edgar Link	pending
diagram_2.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nwbo-20141231.xml	Edgar Link	completed
nwbo-20141231.xsd	Edgar Link	pending
nwbo-20141231_cal.xml	Edgar Link	unprocessable
nwbo-20141231_def.xml	Edgar Link	unprocessable
nwbo-20141231_lab.xml	Edgar Link	unprocessable
nwbo-20141231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v403266_10k.htm	Edgar Link	pending
v403266_ex23-1.htm	Edgar Link	pending
v403266_ex31-1.htm	Edgar Link	pending
v403266_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2015 Q1 Form 10-K Financial Statement

#000114420415016579 Filed on March 17, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2015 Q1 Form 10-K Financial Statement

#000114420415016579 Filed on March 17, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo